Indoco Remedies

Mumbai, India Founded: 1947 • Age: 79 yrs Listed
APIs manufacturing and formulation services are provided in therapeutic segments.
Request Access
Report Incorrect Data
Page last updated

About Indoco Remedies

Indoco Remedies is a publicly listed company based in Mumbai (India) founded in 1947. APIs manufacturing and formulation services are provided in therapeutic segments. The company has 510 employees. Indoco Remedies has completed 2 acquisitions, including FPP Holding Company and Florida Pharmaceutical Products. Its website indoco.com draws about 12 thousand monthly visits. Its Indian entity Indoco Remedies Limited reported revenue of ₹1,852 Cr. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Its competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma; 1 of its 3 listed competitors has raised funding.

Company details

Indoco Remedies was founded in 1947 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) are manufactured alongside formulation services. Coverage includes therapeutic areas such as gastro-intestinal, respiratory, anti-infective, stomatologicals, ophthalmic, nutritionals, cardiovascular, anti-diabetics, and pain management. Leadership is provided by managing directors Sundeep V Bambolkar and Aditi Kare Panandikar.

  • Headquarters Mumbai, India
  • Employees 510
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website indoco.com
  • Social LinkedIn Facebook Instagram
  • Legal Name Indoco Remedies Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹1,982 Cr

    INDOCO · NSE

  • Share Price
    ₹215.06

    +0.16% today

  • Revenue
    ₹1,845 Cr

    FY 2025-26 · +10.8% YoY

  • EBITDA
    ₹135 Cr

    Margin 7.3%

  • Net Profit
    −₹91.69 Cr

    FY 2025-26 · -22.4% YoY

  • ROE
    -10.1%

    ROCE 0.8%

  • Debt / Equity
    1.06

    Interest cover 1,364.4x

  • Investors
    Baring Private Equity Partners
  • Employee Count
    510
  • Investments & Acquisitions
    FPP Holding Company

    & 1 more

Funding Insights of Indoco Remedies

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of Indoco Remedies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2012Post-IPO––
Baring Private Equity Partners
Valuation history

1 investors in total: 1 institutional.

Investors in Indoco Remedies

Indoco Remedies has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Baring Private Equity Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Baring Private Equity Partners
Private equity firm focusing on buyouts and investments in multiple sectors
1998bpepindia.comMumbai, India
Premium access

Investor details for Indoco Remedies

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Indoco Remedies Limited (Indoco Remedies)

Indoco Remedies Limited is the primary company behind Indoco Remedies. The board of Indoco Remedies Limited currently have 7 directors; the longest-serving is Suresh Govind Kare, appointed in 1963. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Suresh Govind Kare
DIN 00179220
Director02 Jul 196363 yrs 4 moIndoco Remedies Limited
Sundeep Vasant Bambolkar
DIN 00176613
Managing Director27 Mar 200422 yrs 7 moIndoco Remedies Limited
Aditi Milind Panandikar
DIN 00179113
Managing Director27 Mar 200422 yrs 7 moIndoco Remedies Limited
Vasudha Vasant Kamat
DIN 07500096
Director27 Mar 20206 yrs 7 moIndoco Remedies Limited
Abhijit Yashawant Gore
DIN 00301688
Director03 Oct 20206 yrs 1 moIndoco Remedies Limited
Satish Madhav Shenoy
DIN 00230711
Director01 Apr 20242 yrs 7 moIndoco Remedies Limited
Ajay Prasan Mulgaokar
DIN 10457626
Director01 Apr 20242 yrs 7 moIndoco Remedies Limited

People of Indoco Remedies

50 people are tracked at Indoco Remedies (18 in leadership, 1 in board & advisors, 31 in team); the tracked headcount is 510.

NameRoleGroup
Sundeep V Bambolkar
Managing DirectorLeadership
Aditi Kare Panandikar
Managing DirectorLeadership
Gaurav A.
Assistant General ManagerLeadership
Sanjay Nirwan
Head Digital MarketingLeadership
Nilesh Bhole
General Manager Human ResourcesLeadership
Rahul Jha
Senior General ManagerLeadership
Rajib Mallick
Senior Vice PresidentLeadership
Vikas Rajput
General Manager International Logistic And EximLeadership
Nikhil Srivastava
General Manager (india Business)Leadership
Vishwanath Hiremath
Assistant General ManagerLeadership
Rajan B Saawant
Vice President- Corporate HRLeadership
Pramod Ghorpade
President Finance And Group CFOLeadership
Ashish Joshi
Associate Vice President | Head Of ProcurementLeadership
Biju Ramachandran
Executive General ManagerLeadership
Girish Nair
Assistant General ManagerLeadership
Susanta Panda
Assistant General ManagerLeadership
Dr Mohmmed Talha Ansari
Deputy General ManagerLeadership
Gopal Devadiga
Sr. General ManagerLeadership
Suresh G. Kare
ChairmanBoard & advisors
Tabrez Shaikh
Sr. Manager - ARDTeam

30 more people are available in the full profile.

Premium access

Complete people profiles for Indoco Remedies

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Indoco Remedies

Indoco Remedies is a publicly listed company on the NSE with ticker symbol INDOCO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Jan 2005
  • Listed onNSE: INDOCO · BSE: 532612
  • Listed entityIndoco Remedies Limited
  • Exchange sectorHealth technology
  • ISININE873D01024
  • Share price₹234.35 (+3.44% on the day) · 2026-10-14
  • Market capitalisation₹2,093 Cr
  • Price to earnings383.4
  • EPS (diluted, trailing year)₹0.61
  • Dividend yield0.09%
  • Volume (last session)236,297

Financials of Indoco Remedies

Exchange-reported figures of Indoco Remedies Limited, the listed company behind Indoco Remedies (NSE: INDOCO).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,845 Cr
+10.8% YoY
EBITDA
₹135 Cr
+36.4% YoY
Profit After Tax
−₹91.69 Cr
-22.4% YoY
Net Worth
₹939 Cr
-8.1% YoY
Total Assets
₹2,068 Cr
+0.4% YoY
Total Debt
₹1,090 Cr
+9.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,8451,6651,8171,6691,5411,2421,107
Revenue growth+10.8%-8.4%+8.9%+8.3%+24.1%+12.2%-
EBITDA13599.26236286327224123
EBITDA margin+7.3%+6.0%+13.0%+17.2%+21.3%+18.1%+11.1%
Profit before tax(106)(74.36)13619323713228.57
Net profit(91.69)(74.94)90.5114315593.2324.30
Net profit margin-5.0%-4.5%+5.0%+8.6%+10.1%+7.5%+2.2%
EPS (₹)(10.31)(7.99)10.6815.4416.8010.102.62
Balance sheet
Total assets2,0682,0601,8281,4021,2001,071977
Net worth9391,0221,1101,028905769680
Total debt1,090994672333257267262
Cash & bank32.9917.0824.3213.3419.7714.3437.93
Net working capital672644643562499378269
Cash flow
Cash from operations19294.9415717917482.22123
Cash from investing(102)(339)(433)(208)(121)(66.69)(55.93)
Cash from financing(76.79)24128022.80(44.37)(29.87)(63.95)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue520468476445485440390411
Revenue growth (YoY)+7.3%+6.3%+21.9%+8.5%+12.0%+1.9%--
Other income39.1199.523.700.980.761.632.021.84
EBITDA46.4341.0249.7125.3642.5217.53(0.78)12.03
EBITDA margin+9.2%+8.8%+10.9%+5.8%+9.0%+4.1%-0.2%+3.0%
Depreciation34.4434.5332.4932.0132.2529.7028.7828.72
Interest26.9128.2945.9225.6424.5626.1217.9816.11
Profit before tax24.1977.72(25.00)(31.31)(13.53)(36.66)(45.52)(30.96)
Tax4.7212.28(1.32)(1.86)(4.32)(0.31)(4.18)(2.56)
Net profit19.4765.44(23.68)(29.45)(9.21)(36.35)(41.34)(28.40)
EPS (₹)2.117.09(2.56)(3.19)(1.00)(3.94)(4.48)(3.08)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,6861,5181,7911,6671,5401,2401,106
Revenue growth+11.1%-15.2%+7.5%+8.3%+24.1%+12.1%-
EBITDA151128250285327224123
EBITDA margin+9.0%+8.4%+14.0%+17.1%+21.2%+18.0%+11.2%
Profit before tax(11.46)(7.36)15319223613128.70
Net profit(3.07)(10.08)10814215592.5624.43
Net profit margin-0.2%-0.7%+6.0%+8.5%+10.1%+7.5%+2.2%
EPS (₹)(0.61)(0.95)12.6515.3416.7710.032.63
Balance sheet
Total assets1,9041,9041,6861,4011,2001,069978
Net worth1,0991,1031,1271,027904769680
Total debt760754514333257258262
Cash & bank20.0012.0316.9412.4019.2114.0537.65
Net working capital654651628559496375267
Cash flow
Cash from operations22610717717917482.17123
Cash from investing(87.38)(276)(302)(209)(121)(66.70)(55.95)
Cash from financing(133)16912222.81(44.37)(29.83)(63.95)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue452409449401442394347373
Revenue growth (YoY)+2.1%+3.7%+29.3%+7.4%+11.5%-1.8%--
Other income42.1610214.037.176.545.586.505.25
Total expenses411367386381389379344353
EBITDA40.2742.2163.0319.8952.8614.823.4620.14
EBITDA margin+9.2%+10.3%+14.7%+5.1%+12.3%+3.8%+1.0%+5.5%
Depreciation27.8628.0526.7127.3627.6325.2024.8824.75
Interest19.8722.7522.7320.1522.0123.6115.9814.00
Profit before tax34.7093.2227.62(20.45)9.76(28.41)(30.90)(13.36)
Tax4.0710.900.27(0.45)(5.29)(0.34)(4.66)(3.13)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue520468476445485440390411
Revenue growth (YoY)+7.3%+6.3%+21.9%+8.5%+12.0%+1.9%--
Other income39.1199.523.700.980.761.632.021.84
EBITDA46.4341.0249.7125.3642.5217.53(0.78)12.03
EBITDA margin+9.2%+8.8%+10.9%+5.8%+9.0%+4.1%-0.2%+3.0%
Depreciation34.4434.5332.4932.0132.2529.7028.7828.72
Interest26.9128.2945.9225.6424.5626.1217.9816.11
Profit before tax24.1977.72(25.00)(31.31)(13.53)(36.66)(45.52)(30.96)
Tax4.7212.28(1.32)(1.86)(4.32)(0.31)(4.18)(2.56)
Net profit19.4765.44(23.68)(29.45)(9.21)(36.35)(41.34)(28.40)
EPS (₹)2.117.09(2.56)(3.19)(1.00)(3.94)(4.48)(3.08)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,8451,6651,8171,6691,5411,2421,107
Revenue growth+10.8%-8.4%+8.9%+8.3%+24.1%+12.2%-
Other income6.796.4529.582.342.333.122.44
Total expenses1,7101,5661,5811,3831,2131,017983
Employee cost426394362323296274257
EBITDA13599.26236286327224123
EBITDA margin+7.3%+6.0%+13.0%+17.2%+21.3%+18.1%+11.1%
Depreciation12611491.8770.6178.9673.1370.82
Interest12266.2338.0225.0314.1422.2626.25
Profit before tax(106)(74.36)13619323713228.57
Tax(7.81)3.5838.7950.5581.7738.954.46
Net profit(91.69)(74.94)90.5114315593.2324.30
Net profit margin-5.0%-4.5%+5.0%+8.6%+10.1%+7.5%+2.2%
EPS (₹)(10.31)(7.99)10.6815.4416.8010.102.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital18.4618.4518.4418.4318.4318.4318.43
Reserves & surplus9211,0041,0911,010886751661
Shareholders' funds (net worth)9391,0221,1101,028905769680
Minority interest(7.17)(3.62)0.600.000.000.000.00
Secured loans866785498267177176194
Unsecured loans22420817466.1479.8790.9967.54
Total debt1,090994672333257267262
Total liabilities2,0682,0601,8281,4021,2001,071977
Assets
Gross block2,2321,9281,7811,4231,2361,1781,127
Net block1,193997954678555570590
Capital work in progress90.0132112511412268.1050.70
Investments1.461.468.712.460.020.020.02
Inventories405419353326311238208
Sundry debtors489352406351297234210
Cash & bank balances32.9917.0824.3213.3419.7714.3437.93
Loans & advances266212164122146137107
Total current assets1,1931,001947813774623563
Total current liabilities521357305250275244294
Net working capital672644643562499378269
Total assets2,0682,0601,8281,4021,2001,071977
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.1114.8610.9217.479.4223.7620.80
Net cash from operating activities19294.9415717917482.22123
Net cash from investing activities(102)(339)(433)(208)(121)(66.69)(55.93)
Net cash from financing activities(76.79)24128022.80(44.37)(29.87)(63.95)
Net change in cash13.82(2.75)3.93(6.54)8.05(14.34)2.97
Closing cash32.9917.0824.3213.3419.7714.3437.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.8%-8.4%+8.9%+8.3%+24.1%+12.2%-
EBITDA growth+36.4%-58.0%-17.5%-12.6%+46.0%+82.1%-
PBT growth-43.2%--29.6%-18.5%+79.2%+362.1%+9998.0%
Net income growth-22.4%-182.8%-36.8%-7.7%+66.4%+283.7%-
Revenue CAGR (3Y)+3.4%+2.6%+13.5%+14.7%+16.7%+6.0%+1.0%
EBITDA CAGR (3Y)-22.1%-32.8%+1.7%+32.4%+62.3%+18.5%-7.7%
Profitability & leverage
Net income margin-5.4%-4.7%+5.3%+8.5%+10.1%+7.5%+2.2%
Return on capital employed+0.8%-0.4%+10.8%+16.7%+22.1%+15.1%+5.6%
Return on net worth-10.1%-7.3%+9.1%+14.7%+18.5%+12.9%+3.6%
Debt / equity1.060.780.470.300.310.360.42
Long-term debt / equity0.630.480.280.160.130.140.17
Interest cover1,364.40-454.2526.3611.625.6914.7350.11
Efficiency & per share
Fixed asset turnover0.890.901.131.261.281.081.07
Inventory turnover4.484.315.355.245.625.575.65
Debtors turnover4.394.394.805.155.805.595.45
EPS (₹)(10.31)(7.99)10.6815.4416.8010.102.62
Dividend per share (₹)0.200.201.502.252.251.500.30
Book value per share (₹)101.76110.79120.40111.5898.1783.4573.75
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue452409449401442394347373
Revenue growth (YoY)+2.1%+3.7%+29.3%+7.4%+11.5%-1.8%--
Other income42.1610214.037.176.545.586.505.25
Total expenses411367386381389379344353
EBITDA40.2742.2163.0319.8952.8614.823.4620.14
EBITDA margin+9.2%+10.3%+14.7%+5.1%+12.3%+3.8%+1.0%+5.5%
Depreciation27.8628.0526.7127.3627.6325.2024.8824.75
Interest19.8722.7522.7320.1522.0123.6115.9814.00
Profit before tax34.7093.2227.62(20.45)9.76(28.41)(30.90)(13.36)
Tax4.0710.900.27(0.45)(5.29)(0.34)(4.66)(3.13)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,6861,5181,7911,6671,5401,2401,106
Revenue growth+11.1%-15.2%+7.5%+8.3%+24.1%+12.1%-
Other income33.1019.4828.242.332.323.112.43
Total expenses1,5351,3901,5411,3821,2131,017983
Employee cost394369351321295273255
EBITDA151128250285327224123
EBITDA margin+9.0%+8.4%+14.0%+17.1%+21.2%+18.0%+11.2%
Depreciation10798.2587.9870.6078.9573.1270.81
Interest88.5056.6336.8125.0314.1422.2226.25
Profit before tax(11.46)(7.36)15319223613128.70
Tax(5.81)1.3636.5850.2381.7138.954.46
Net profit(3.07)(10.08)10814215592.5624.43
Net profit margin-0.2%-0.7%+6.0%+8.5%+10.1%+7.5%+2.2%
EPS (₹)(0.61)(0.95)12.6515.3416.7710.032.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital18.4618.4518.4418.4318.4318.4318.43
Reserves & surplus1,0811,0851,1081,009886750662
Shareholders' funds (net worth)1,0991,1031,1271,027904769680
Secured loans522508328267177165184
Unsecured loans23824618666.1479.8793.4477.54
Total debt760754514333257258262
Total liabilities1,9041,9041,6861,4011,2001,069978
Assets
Gross block1,8511,6661,5551,4061,2361,1781,127
Net block851754732661555570590
Capital work in progress85.2122611411312268.1050.70
Investments16051.9659.2019.902.462.452.45
Inventories322363310326311238208
Sundry debtors541374408351297234209
Cash & bank balances20.0012.0316.9412.4019.2114.0537.65
Loans & advances231190158122146136107
Total current assets1,114939893811773622562
Total current liabilities460288265253277247294
Net working capital654651628559496375267
Total assets1,9041,9041,6861,4011,2001,069978
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash7.067.479.9916.909.1323.4820.72
Net cash from operating activities22610717717917482.17123
Net cash from investing activities(87.38)(276)(302)(209)(121)(66.70)(55.95)
Net cash from financing activities(133)16912222.81(44.37)(29.83)(63.95)
Net change in cash5.87(0.41)(2.52)(6.91)7.77(14.35)2.76
Closing cash20.0012.0316.9412.4019.2114.0537.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.1%-15.2%+7.5%+8.3%+24.1%+12.1%-
EBITDA growth+17.8%-48.7%-12.3%-12.9%+46.3%+81.3%-
PBT growth-55.7%--20.0%-18.9%+79.9%+357.6%+9998.0%
Net income growth+69.5%-109.3%-24.0%-8.1%+67.3%+278.9%-
Revenue CAGR (3Y)+0.4%-0.5%+13.0%+14.7%+16.7%+6.1%+1.0%
EBITDA CAGR (3Y)-19.1%-26.8%+3.8%+32.2%+62.1%+18.4%-7.7%
Profitability & leverage
Net income margin-0.3%-0.6%+6.5%+8.5%+10.0%+7.5%+2.2%
Return on capital employed+4.2%+2.7%+12.3%+16.7%+22.1%+15.0%+5.6%
Return on net worth-0.3%-0.9%+10.8%+14.6%+18.5%+12.8%+3.6%
Debt / equity0.690.570.390.310.310.360.42
Long-term debt / equity0.310.250.190.140.120.130.17
Interest cover201.41190.1022.7511.685.7014.7749.98
Efficiency & per share
Fixed asset turnover0.960.941.211.261.281.081.07
Inventory turnover4.934.515.635.245.625.565.65
Debtors turnover3.683.884.725.155.805.605.48
EPS (₹)(0.61)(0.95)12.6515.3416.7710.032.63
Dividend per share (₹)0.200.201.502.252.251.500.30
Book value per share (₹)119.08119.61122.22111.4598.1383.4473.81

Investments & Acquisitions by Indoco Remedies

Indoco Remedies has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include FPP Holding Company and Florida Pharmaceutical Products.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Florida Pharmaceutical Products
Generic solid and liquid dosage forms are manufactured.
flpharmaproducts.comBoca Raton, United States1999Jun 2023$4M
FPP Holding Company
Generic pharmaceutical products are distributed and marketed through specialized services.
Florida, United States0Jun 2023$4M
Premium access

Complete acquisition details for Indoco Remedies

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Indoco Remedies

5 dated milestones of Indoco Remedies across 76 years, from founding to its latest funding, stage changes and deals.

  1. Founded Indoco Remedies is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round.
  4. Acquisition Acquires Florida Pharmaceutical Products.
  5. Acquisition Acquires FPP Holding Company.

Competitors of Indoco Remedies

Indoco Remedies has 3 listed competitors in our database, 1 of them funded. They include Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
BDR Pharmaceuticals Internationals
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Aurobindo Pharma
aurobindo.com1986Hyderabad, India1,010
Generic biocatalytic solutions are provided for pharmaceutical applications.
Premium access

Detailed competitors of Indoco Remedies

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Indoco Remedies

The website of Indoco Remedies (indoco.com) receives about 11.8K visits a month and ranks #1,452,218 among all websites worldwide, #1,895 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    11.8K

    ▼ 14.3% vs previous month

  • Unique visitors
    6.9K

    per month

  • Global rank
    #1,452,218

    among all websites

  • Category rank
    #1,895

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Indoco Remedies. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Calyx Chemicals and Pharmaceuticals
calyxindia.com
100%
1K#7,901,342View details
Mangalam Drugs
mangalamdrugs.com
94%
9.9K#1,747,627View details
Rusan Pharma
rusanpharma.com
92%
4K#3,386,749View details
Pharmaguddu
pharmaguddu.com
88%
#1,114,765View details
Advanz Pharmaceutical
advanzpharma.com
87%
7K#2,512,187View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 31 similar websites and full traffic analytics for Indoco Remedies

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 31 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Indoco Remedies (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Indoco Remedies

INDOCO: Q2 EBITDA 464M RUPEES VS 431M (YOY); Q2 EBITDA MARGIN 8.9% VS 8.9% (YOY)
Exchange Update • 12 days ago
INDOCO: Q2 CONS NET PROFIT 184M RUPEES VS LOSS 79M (YOY); EST LOSS 93M
Exchange Update • 12 days ago
INDOCO: Q2 REVENUE 5.2B RUPEES VS 4.8B (YOY)
Exchange Update • 12 days ago
Indoco Remedies: Launches Fully-Owned Subsidiary Warren Lifesciences For Pharma Production
Exchange Update • 1 month ago
INDOCO: EBITDA margin and revenue rose on U.S. and API growth, with efficiency gains and positive outlook
Quartr • 3 months ago
Indoco Remedies Appoints Aditi Panandikar As MD
Reuters • 3 months ago
INDOCO: Q1 revenue up 6% YoY, EBITDA margin rises, and profit boosted by Ophthalmic Division sale
Quartr • 3 months ago
Indoco Remedies June-Quarter Consol Net Profit 649.9 Million Rupees
Reuters • 3 months ago
Indoco Remedies share price gains after Goa plant receives EU GMP certification
Moneycontrol • 4 months ago
Buzzing Stocks: Indoco Remedies jumps 4% on EU GMP nod; Bata India slips 3% after weak Q4
Moneycontrol • 5 months ago
Premium access

Complete news archive for Indoco Remedies

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Indoco Remedies

Indoco Remedies was founded in 1947 and raised its 1st funding round 65 years after it was founded.

Indoco Remedies is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Indoco Remedies has 510 employees.

The primary company behind Indoco Remedies, Indoco Remedies Limited, reported revenue of ₹1,852 Cr for FY 2026, up 11% year on year.

Indoco Remedies was founded in 1947 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) are manufactured alongside formulation services. Coverage includes therapeutic areas such as gastro-intestinal, respiratory, anti-infective, stomatologicals, ophthalmic, nutritionals, cardiovascular, anti-diabetics, and pain management. Leadership is provided by managing directors Sundeep V Bambolkar and Aditi Kare Panandikar.

Indoco Remedies's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma.

Yes, Indoco Remedies is publicly traded on NSE under the ticker symbol INDOCO.

Indoco Remedies has made 2 acquisitions, including FPP Holding Company, and Florida Pharmaceutical Products.

Indoco Remedies has 1 investor. Key investors include Baring Private Equity Partners.

Indoco Remedies operates through Indoco Remedies Limited.

The legal entities of Indoco Remedies currently have 9 directors, including Suresh Govind Kare, Sundeep Vasant Bambolkar, Aditi Milind Panandikar and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available